Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
  • ECCO 2022
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018

Labiotech

December 15, 2018

Abivax Spots an Extra Benefit of its Potential HIV Cure

Labiotech

November 6, 2018

Potential HIV Cure Shows Early Stage Promise

Healio

September 6, 2018

Ulcerative colitis drug shows efficacy in European phase 2 trial

Drug Development Technology

September 5, 2018

Abivax reports positive topline results from ABX464-101 trial for UC

IBD News Today

September 5, 2018

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

  • 1
  • 2
  • 3
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+